Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $68.97, for a total value of $11,466,262.50. Following the completion of the sale, the chief executive officer directly owned 9,041,283 shares in the company, valued at approximately $623,577,288.51. The trade was a 1.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tempus AI Trading Down 4.9%

Shares of NASDAQ:TEM traded down $3.40 on Thursday, reaching $65.69. 7,149,431 shares of the company traded hands, compared to its average volume of 6,352,496. The business’s 50-day simple moving average is $83.96 and its 200 day simple moving average is $71.87. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32. The stock has a market capitalization of $11.69 billion, a P/E ratio of -55.20 and a beta of 4.86.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. During the same period last year, the firm earned ($0.46) earnings per share. Tempus AI’s quarterly revenue was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Morgan Stanley raised their price target on Tempus AI from $68.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Needham & Company LLC raised their target price on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Piper Sandler reduced their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Finally, BTIG Research reissued a “buy” rating and set a $96.00 target price on shares of Tempus AI in a research report on Wednesday, November 5th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $80.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. ARK Investment Management LLC increased its position in Tempus AI by 35.9% during the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company’s stock worth $361,867,000 after buying an additional 1,981,755 shares in the last quarter. Vanguard Group Inc. raised its stake in Tempus AI by 6,247.5% during the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock worth $289,204,000 after purchasing an additional 5,900,668 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Tempus AI by 109.9% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 50,666 shares of the company’s stock valued at $2,444,000 after acquiring an additional 26,533 shares during the last quarter. Jump Financial LLC purchased a new stake in shares of Tempus AI during the 1st quarter worth about $8,545,000. Finally, Tyler Stone Wealth Management acquired a new stake in Tempus AI in the 1st quarter valued at $386,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.